{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Carrat F"],"funding":["ANR (Agence Nationale de la Recherche)","Agence Nationale de la Recherche","Inserm (Institut National de la Santé et de la Recherche Médicale) [#C20-26]","ANR","Inserm (Institut National de la Santé et de la Recherche Médicale) [#C20–26]","Fondation pour la Recherche Médicale","Fondation pour la Recherche Médicale [#20RR052-00], Inserm (Institut National de la Santé et de la Recherche Médicale) [#C20-26]"],"pagination":["1458-1472"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8344948"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["50(5)"],"pubmed_abstract":["<h4>Background</h4>We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors.<h4>Methods</h4>Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike pr"],"journal":["International journal of epidemiology"],"pubmed_title":["Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study."],"pmcid":["PMC8344948"],"funding_grant_id":["#ANR-10-COHO-06","#ANR-20-COVI-000, #ANR-10-COHO-06","#20RR052-00","#ANR-20-COVI-000"],"pubmed_authors":["Artaud F","Severi G","Lai C","for the SAPRIS and SAPRIS-SERO study groups","Zins M","de Lamballerie X","Jusot F","Kab S","Fourie T","Legot S","Nicol J","Bajos N","Saba Villarroel PM","Rahib D","Druesne-Pecollo N","Priet S","Renuy A","Gagliolo JM","Lusivika-Nzinga C","Lapidus N","Touvier M","Szabo de Edelenyi F","Ancel PY","Esseddik Y","Lydie N","Blanche H","Meyer L","Rouquette A","Carrat F","Deleuze JF","Charles MA"],"additional_accession":[]},"is_claimable":false,"name":"Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.","description":"<h4>Background</h4>We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors.<h4>Methods</h4>Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike pr","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-07-16T09:09:20.261Z","creation":"2022-02-11T16:10:12.159Z"},"accession":"S-EPMC8344948","cross_references":{"pubmed":["34293141"],"doi":["10.1093/ije/dyab110"]}}